NEW YORK (GenomeWeb) – Xagenic today announced it has acquired exclusive rights to a mutation detection technology developed at the University of Toronto that could be used in liquid biopsy testing.

The electrochemical clamp assay technology detects specific SNPs and genetic mutations in cell-free nucleic acids in blood plasma or serum. Xagenic said the acquisition could enable the Xagenic X1 platform to expand into blood-based or liquid biopsy testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.